FBXO22 and breast cancer: One study showed that a patient-derived tryptophan-to-arginine mutation at residue 52 (W52R) within the F-box domain impaired FBXO22 binding to the SKP1–Cullin1 complex, thus blocking FBXO22-mediated snail family transcriptional repressor 1 (SNAIL) degradation and abrogating FBXO22 suppression of breast cancer cell migration, invasion, and metastasis (7).